← ANALYST RATINGS · TIPRANKS
Amylyx Pharmaceuticals Inc (AMLX): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
$46.62+77.0% upside
Based on 9 price targets given in the last 3 months, the average target is $46.62, the highest $57.00, the lowest $39.00. The average is +77.0% from the last price of $26.34.
Highest target $57.00
Average target $46.62
Lowest target $39.00
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $29.00 → $28.00−3.4% | Hold | +6.3% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $28.00−3.4% | Hold | +6.3% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $29.00 → $28.00−3.4% | Hold | +6.3% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $29.00 → $28.00−3.4% | Hold | +6.3% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $30.00−3.2% | Buy | +13.9% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $29.00 → $28.00−3.4% | Hold | +6.3% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $30.00 → $31.00+3.3% | Buy | +17.7% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $32.00 → $39.00+21.9% | Buy | +48.1% | Reiterated | 15.10.26on TipRanks 05:55 | +2.0%next day −3.6% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $30.00−3.2% | Buy | +13.9% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $32.00 → $31.00−3.1% | Buy | +17.7% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $30.00 → $32.00+6.7% | Buy | +21.5% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $31.00 → $30.00−3.2% | Buy | +13.9% | Reiterated | 10.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 08.10.26on TipRanks Oct 7 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 08.10.26on TipRanks Oct 7 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 08.10.26on TipRanks Oct 7 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $29.00 → $30.00+3.4% | Hold | +13.9% | Reiterated | 08.10.26on TipRanks Oct 7 21:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 03.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 03.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 03.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $30.00 → $29.00−3.3% | Hold | +10.1% | Reiterated | 03.10.26on TipRanks 04:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $31.00 → $30.00−3.2% | Hold | +13.9% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $31.00 → $30.00−3.2% | Hold | +13.9% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $31.00 → $30.00−3.2% | Hold | +13.9% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $31.00 → $30.00−3.2% | Hold | +13.9% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $33.00 → $31.00−6.1% | Buy | +17.7% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $31.00 → $30.00−3.2% | Hold | +13.9% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $45.00 | Buy | +70.8% | Reiterated | 01.10.26on TipRanks 10:15 | −3.7%next day −1.8% · 5 days −4.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $36.00 → $31.00−13.9% | Hold | +17.7% | Reiterated | 01.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $36.00 → $31.00−13.9% | Hold | +17.7% | Reiterated | 01.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $36.00 → $31.00−13.9% | Hold | +17.7% | Reiterated | 01.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $36.00 → $31.00−13.9% | Hold | +17.7% | Reiterated | 01.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $38.00 → $33.00−13.2% | Buy | +25.3% | Reiterated | 01.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $36.00 → $31.00−13.9% | Hold | +17.7% | Reiterated | 01.10.26on TipRanks 02:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $37.00 → $36.00−2.7% | Hold | +36.7% | Reiterated | 09.09.26on TipRanks Sep 8 22:00 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $36.00 | Hold | +36.7% | Reiterated | 09.09.26on TipRanks Sep 8 22:00 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $35.00 → $36.00+2.9% | Hold | +36.7% | Reiterated | 09.09.26on TipRanks Sep 8 22:00 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $35.00 → $36.00+2.9% | Hold | +36.7% | Reiterated | 09.09.26on TipRanks Sep 8 22:00 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $38.00 | Buy | +44.3% | Reiterated | 09.09.26on TipRanks Sep 8 22:00 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $36.00 | Hold | +36.7% | Reiterated | 09.09.26on TipRanks Sep 8 22:00 | — | |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $55.00 → $57.00+3.6% | Buy | +116.4% | Assigned | 26.08.26on TipRanks Aug 27 07:10 | −1.0%next day −0.4% · 5 days −6.9% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $24.00 → $44.00+83.3% | Buy | +67.0% | Reiterated | 22.08.26on TipRanks 15:30 | −1.0%next day −2.1% · 5 days −12.0% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $34.00 → $55.00+61.8% | Buy | +108.8% | Reiterated | 20.08.26on TipRanks Aug 18 12:25 | +64.5%next day +9.7% · 5 days +6.9% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $26.00 → $32.00+23.1% | Buy | +21.5% | Reiterated | 19.08.26on TipRanks Aug 18 10:17 | +64.5%next day +9.7% · 5 days +6.9% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $30.00 → $42.00+40.0% | Buy | +59.5% | Reiterated | 19.08.26on TipRanks Aug 17 06:32 | −0.5%next day +64.5% · 5 days +79.2% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 18.08.26on TipRanks Aug 19 09:40 | +64.5%next day +9.7% · 5 days +6.9% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $39.00 | Buy | +48.1% | Reiterated | 18.08.26on TipRanks Aug 19 04:45 | +64.5%next day +9.7% · 5 days +6.9% | ↗ |
| Christopher Chen★★★★★★★★★★#5006 · hits 100% · avg +66.9% | Robert W. Baird | $28.00 → $52.00+85.7% | Buy | +97.4% | Reiterated | 18.08.26on TipRanks 15:10 | +64.5%next day +9.7% · 5 days +6.9% | ↗ |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | — | Buy | — | Reiterated | 18.08.26on TipRanks 10:17 | +64.5%next day +9.7% · 5 days +6.9% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $22.00 → $23.00+4.5% | Buy | −12.7% | Reiterated | 18.06.26on TipRanks 08:10 | +1.7%next day +4.2% · 5 days +15.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Amylyx Pharmaceuticals Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.75 at a price of $29.10 (+57.2%); now: $46.62 at $26.34 (+77.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 10 | 10 | 7 | 3 | 3 |
| Buy | 13 | 8 | 7 | 18 | 17 | 16 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.38 (from $-0.43 to $-0.31). Last quarter: $-0.39.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Amylyx Pharmaceuticals Inc
- CEO: Joshua Cohen
- Employees: 136
- 55 Cambridge Parkway, Cambridge, MA, 02142, US
- amylyx.com
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 50 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗